Publications

Etrasimod

22
Apr '17

ASPET 2017 at Experimental Biology (EB)


Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors
Download Abstract

Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected with Colitogenic CD4+ T Cells
Download Abstract

Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors
Download Abstract

7
Mar '17

Autoimmunity Reviews


Modulation of sphingosine-1-phosphate in inflammatory bowel disease
View PDF

17
Feb '17

12th Congress of European Crohn’s and Colitis Organisation (ECCO) – Inflammatory Bowel Diseases 2017


Safety, tolerability and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers
Download Poster

DOP077 Immunomodulatory Effects of Etrasimod APD334 an Oral Potent
Download Abstract

DOP078 Pharmacology and Safety of Etrasimod APD334 an Oral Potent
Download Abstract

9
Dec '16

Advances in Inflammatory Bowel Diseases (AIBD) Meeting


Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral, Selective S1P Receptor Modulator, after Single Dose Escalation in Healthy Volunteers
View Poster

Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Preclinical Autoimmune Disease-modifying Activity Exhibits Favorable PK/PD Properties in Healthy Volunteers
View Poster

Preclinical Safety Assessment of Etrasimod (APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator with a Favorable Profile
View Poster

The Sphingosine-1-Phosphate Receptor (S1P) Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart Rate in Preclinical Testing
View Poster

18
Oct '16

United European Gastroenterology Week (UEGW) Meeting


Abstract 5531 – Receptor Profile and Efficacy of Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator in Development for Ulcerative Colitis
View Abstract

Ralinepag

29
Aug '17

European Society of Cardiology Congress (ESC) 2017


APD811 (ralinepag), a novel non-prostanoid IP receptor agonist, has potent antiproliferative and vasorelaxant properties in human pulmonary artery
View Abstract

Comparative receptor pharmacology, pre-clinical efficacy and pharmacokinetics of a novel, next-generation prostacyclin receptor agonist, ralinepag (APD811), in humans and rats
View Abstract

23
May '17

American Thoracic Society (ATS) 2017 International Conference


Safety and Pharmacokinetics of Ralinepag (APD811), a Next-generation, Selective Prostacyclin Receptor Agonist, in Healthy Adult Subjects
View Poster

10
Jan '17

Journal of Medicinal Chemistry


Discovery of 2‑(((1r,4r)‑4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
View PDF

14
Nov '16

American Heart Association (AHA) Meeting


APD811, a Novel and Highly Selective Non-prostanoid IP Receptor Agonist in Smooth Muscle Cells From Patients With Pulmonary Hypertension
View Poster